Publication: Bisphosphonate therapy for refractory langerhans cell histiocytosis: A case report
Issued Date
2015-11-01
Resource Type
ISSN
01252208
Other identifier(s)
2-s2.0-84949951880
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of the Medical Association of Thailand. Vol.98, No.11 (2015), 1145-1149
Suggested Citation
Chayamon Takpradit, Nassawee Vathana, Nattee Narkbunnam, Kleebsabai Sanpakit, Jassada Buaboonnam Bisphosphonate therapy for refractory langerhans cell histiocytosis: A case report. Journal of the Medical Association of Thailand. Vol.98, No.11 (2015), 1145-1149. Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/36264
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Bisphosphonate therapy for refractory langerhans cell histiocytosis: A case report
Other Contributor(s)
Abstract
© 2015, Medical Association of Thailand. All rights reserved. Although patients diagnosed as Langerhans cell histiocytosis (LCH) with bone lesion initially respond well to treatment, some may experience relapse or refractory disease. Pamidronate, a potent N-bisphosphonate, has been used in several primary bone diseases, benign bone tumors, and metastatic bone cancers. The mechanism includes an inhibitory effect on osteoclast activity by decreasing development and recruitment of osteoclast progenitors and promoting osteoclast apoptosis. Herein, we introduce a seven-month-old Thai girl who was diagnosed as multiple-relapse LCH with refractory bone lesions and was treated with standard and salvage steroid-based therapies. After receiving two courses of intravenous pamidronate, she had marked clinical and radiographical improvement without any adverse events. She has been in remission for two years after receiving six courses of therapy. This report supports the efficacy of pamidronate in LCH-related bone lesions, but further studies in large cohort are warranted.